Aim: To evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and active exudation or hemorrhage.
Methods: Prospective, open-label, investigator-sponsored trial of monthly intravitreal ranibizumab (0.5 mg) for PCV. Primary outcomes are stabilization of vision (loss <15 ETDRS letters) and incidence of ocular and systemic adverse events. Secondary outcome measures are changes in visual acuity, subretinal or sub-retinal pigmented epithelial hemorrhage, subretinal exudates, central foveal thickness (CFT), fluorescein leakage and polypoidal complexes.
Results: Eight patients (8 eyes) finished the 6-month treatment. No significant adverse events were noticed. No patient lost ≥15 letters. Fluorescein leakage decreased in 6 of 8 eyes. Hemorrhage decreased in 6 of 6 eyes. Exudates decreased in 3 of 5 eyes, but increased in 1 eye. CFT decrease from 351μm at baseline to 298μm at 6 months. The polypoidal complexes remained stable in 6 of 8 eyes, and decreased in 2 eyes.
Conclusions: Continuous monthly intravitreal ranibizumab is safe and well tolerated in eyes with PCV. Preliminary results show stabilization of vision, resolution of subretinal hemorrhage, decrease of macular edema and persistence of polypoidal complexes, although two eyes showed regression of polyps.